Italian study shows no improvement from Roche's rheumatoid arthritis drug for COVID-19

Roche Holding AG's Actemra did not improve symptoms in patients with early-stage COVID-19 pneumonia, scientists conducting a study of the drug in Italy said on Wednesday, raising questions about the potential of the Swiss drugmakers' rheumatoid arthritis drug to treat the novel coronavirus.